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The implantable cardioverter-defibrillator (ICD) has established itself as life-saving therapy
in patients at risk for sudden cardiac death. Remarkable technological advances have made
ICDs easier and safer to implant, with improved therapeutic and diagnostic functions and
reduced morbidity.
Guidelines on ICD indications have been proposed by American and European scientific
societies since a number of years, based upon trials and expert opinion. In the context of
variable economic and political constraints, it is questionable whether these guidelines
may be applied to all settings. This review discusses the guideline-based indications,
critically examines their applicability to clinical practice, and discusses alternatives to ICD
therapy.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Implantable cardioverter defibrillators (ICDs) were
approved for general market release in the United States in
1985, but only for patients who had survived prior cardiac
death (SCD). Over the last two decades, the indications have
evolved from secondary prevention of sudden death to also
include primary prevention in selected patients. The most
recent international guidelines that include indications for
ICDs are the 2006 ACC/AHA/ESC guidelines on ventricular
arrhythmias and sudden death,1 the 2012 update of the 2008
ACC/AHA/HRS device guidelines,2 and the 2012 ESC guide-
lines on heart failure.3 The main ICD indications are
summarized in Table 1 and their rationale are discussed
below.f Geneva, Rue Perret-Gen
. Burri).
2013, Cardiological Socie2. Secondary prevention
Secondary prevention refers to prevention of SCD in pa-
tients who have survived a prior sudden cardiac arrest or
sustained ventricular tachycardia (VT).2 Early data on ICDs
were drawn primarily from uncontrolled series of refractory
patients who had failed antiarrhythmic drugs. In the 1990’s,
three randomized controlled trials of secondary prevention of
sudden death were conducted: AVID,4 CASH5 and CIDS.6 All
three trials enrolled patients who had survived SCD without a
reversible cause. The trials randomized an ICD to antiar-
rhythmic therapy (including amiodarone, sotalol or prop-
afenone). A meta-analysis of these trials7 including 1866
patients showed that ICD therapy significantly reduced the
risk of total mortality by 28% (p ¼ 0.0006) and that of suddentil 4, CH e 1211, Geneva 14, Switzerland. Tel.: þ41 22 372 72 00; fax:
ty of India. All rights reserved.
Table 1 e Summary of the main ICD indications of the latest international guidelines.
Patient characteristics ACC/AHA/ESC ventricular
arrhythmia and sudden death 20061
ACCF/AHA/HRS device-based
therapy 20122
ESC heart
failure 20123
Cardiac arrest survivors,
unstable sustained VT
Class I, LOE A Class I, LOE A Class I, LOE A
Structural heart disease,
spontaneous sustained VT
(stable or unstable)
e Class I, LOE B e
Post MI (‡40 days)
NYHA II, III LVEF 35%: Class I, LOE A (LVEF 30e40%) Class I, LOE A Class I, LOE A
NYHA I LVEF 30%: Class IIa, LOE B (LVEF 30e35%) Class I, LOE A e
LVEF 40%, NSVT, EPS+ Class I, LOE A Class I, LOE B
NICM LVEF £35%
NYHA II, III Class I, LOE B (LVEF 30e35%) Class I, LOE B Class I, LOE B
NYHA I Class IIb, LOE C (LVEF 30e35%) Class IIb, LOE C e
Shaded gray boxes: secondary prevention; white boxes: primary prevention.
Abbreviations: EPS+: induction of sustained ventricular tachycardia or ventricular fibrillation at electrophysiological study; LOE: level of evi-
dence; MI: myocardial infarction; NICM: non-ischemic cardiomyopathy; VT: ventricular tachycardia; VF: ventricular fibrillation.
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these trials, the guidelines state that:
ICD implantation is a class I level of evidence A indication in
survivors of sudden death due to ventricular fibrillation (VF) or
hemodynamically unstable sustained ventricular tachycardia
(VT), after a completely reversible cause has been excluded.
Secondary prevention of sudden death (without a revers-
ible cause for arrhythmia) is seldom disputed as being an
indication for an ICD. However, subgroup analyses (with all
their caveats) indicate that not all patients benefit from this
therapy. In the meta-analysis of AVID/CIDS/CASH, patients
aged >75 years did not benefit from the ICD.8 In AVID, the
largest of all the secondary prevention trials, patients with a
left ventricular ejection fraction (LVEF) of >34% (comprising
approximately 40% of the study population), also did not
derive any survival benefit from ICD therapy.9 In the setting of
limited resources, these subgroup analyses call for careful
evaluation in order to prescribe therapy to those patients who
are most likely to benefit, even in the setting of secondary
prevention.
The AVID registry10 showed that patients who presented
with sustained VT without serious symptoms or hemody-
namic compromise (and who were not implanted with an
ICD), also had a high mortality. The presenting arrhythmias
may be a marker for a substrate capable of producing a more
malignant arrhythmia. Therefore, current guidelines state
that:
ICD therapy is a class I indication in patients with structural
heart disease and spontaneous sustained VT, whether hemody-
namically stable or unstable.
ICD implantation is however not indicated in certain VTs in
patients with structurally normal hearts, such as infundibular
or fascicular VTs who generally have a good prognosis and in
whom catheter ablation may be curative.2
In patients with structural heart disease, an
electrophysiological study (EPS)-guided approach withantiarrhythmic therapy has been evaluated. A study11
included 84 patients with ischemic heart disease who pre-
sented with sustained VT or VF and in whom arrhythmias
were inducible at EPS; half of the patients were no longer
inducible after amiodarone loading. The non-inducible pa-
tients were then maintained on amiodarone, and an ICD was
implanted in the others. After a mean follow-up of 5 years,
total mortality and sudden cardiac death were significantly
higher in the patients only on amiodarone therapy, indicating
that this strategy does not offer optimal protection. Amio-
darone may nevertheless be considered (class IIb, level of
evidence C) in patients with LV dysfunction due to prior MI
with an ICD indication, in patients who cannot (e.g. for
financial reasons) or refuse to have an ICD implanted.1
Another alternative to ICD implantation that may be
considered is catheter ablation of ventricular arrhythmias, a
domain in which increasing experience is being gained. In a
2009 EHRA/HRS expert consensus statement,12 catheter abla-
tion was proposed as an adjunct to ICD therapy but not as an
alternative to it. It is stated that “results of catheter ablation of
VT should have little influence on the indications for ICD
implantation”, as even if VTs are rendered non-inducible by
ablation, the recurrence rate may remain substantial. This
was observed in the multicentre VTACH study,13,14 in which
107 ICD patients with ischemic heart disease, reduced (50%)
LVEF and a history of stable VT were randomized 1:1 to
catheter ablation versus conventional therapy. Even though
VT/VF recurrence was significantly reduced in patients ran-
domized to ablation, ventricular arrhythmias still recurred in
half of them.
A stepwise approach in patients with ischemic heart dis-
ease presenting with sustained VT has been published.15 In
this report, 45 patients with a mean LVEF of 40% underwent
radiofrequency ablation of VT, the endpoint of which was
non-inducibility, and which was acutely successful in 89% of
patients. The EPS was repeated at 2e3 months (without anti-
arrhythmic drugs) and in case of re-inducibility, and new
ablation procedure was performed. Patients in whom mono-
morphic VT of <270 bpm remained inducible despite radio-
frequency ablation were implanted with an ICD. Thus only 19/
Fig. 1 e Comparison of results of primary (left) and
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 8 2es 8 7S8445 (42%) of patients had ICD implantation. After a median
follow-up of 45 months, there were no significant differences
in mortality between the two groups (p ¼ 0.11), with a trend in
better survival in patients without an ICD. Only 1 patient
without an ICD died suddenly (and may therefore have
benefited from ICD implantation). These very promising re-
sults however need to be interpreted with caution, namely
that the procedures were performed in an expert center, using
state-of-the art techniques and technology (such as electro-
anatomical mapping). The results therefore may not be
extrapolated to centers with less experience/infrastructure,
but nevertheless offer a future perspective to a cheaper
alternative to ICDs.secondary (right) prevention ICD trials. ARR[ absolute risk
reduction.
3. Primary prevention of sudden death
This indication is more a subject of debate than secondary
prevention, especially as trials have gradually included pa-
tients with less stringent selection criteria. A summary of the
ICD indications stated in different guidelines is shown in
Table 1.
3.1. Patients with ischemic heart disease
Three studies have randomized patients with ischemic
heartdiseaseandreducedLVEF toconventional therapyversus
an ICD for primary prevention of sudden death: MADIT,16
MUSTT,17 and MADIT II.18 The first two studies included pa-
tients with an LVEF of 35% and 40% respectively, with
documented non-sustained VT, and inducible VT by EPS that
was not suppressible by anti-arrhythmic drugs. MADIT II was
the largest study (1232 patients) and did not require docu-
mentationof arrhythmiasor inducibleVT for inclusion, but the
LVEF cutoff was lower at 30%. All three studies showed a
reduction in mortality in ICD patients. Based upon the results
of MADIT and MUSTT, the guidelines state that:
Patients with ischemic heart disease and LVEF 40%, non-
sustained VT and inducible VT or VF by an EPS have a class I
indication for an ICD.
Based upon MADIT II, the guidelines state that:
Patients with an LVEF 30% and ischemic heart disease have a
class I indication for an ICD (without documenting any ventric-
ular arrhythmias, and independently of heart failure status;
cutoff of LVEF is35% in patients with NYHA II-III heart failure).
The guidelines also state that life expectancy should be
>1 year, and that the interval between myocardial infarction
and ICD implantation should be >40 days, and that in case
of heart failure, that optimal medical therapy should
have been followed for 3 months. This was due to two
studies19,20 that showed not survival benefit if ICDs were
implanted early after myocardial infarction. This was
attributed to the possibility that ICDs, by shocking VF in
these patients, merely transform sudden death to eventual
death from pump failure, without significantly prolonging
life.A subgroup analysis of the MADIT study showed that “the
sickest patients benefit the most”, as efficacy of the ICD was
limited to those with an LVEF <26%.21 In MADIT-II, subgroup
analysis also showed that only patients with an LVEF <25%
had a statistically significant improvement in survival
conferred by the ICD, although there was a trend in
improvement in patients with an LVEF >25%. Inducibility of
VT by an EPS is sometimes used for risk-stratification in order
to aim for a target population who would be most likely to
benefit from an ICD. In the MADIT II study however, patients
without VT inducibility still had a 25% incidence of ventricular
arrhythmias at follow-up that was not statistically different
from those patients who were inducible.22 This implies that
an EPS has limited value in a MADIT-II type patient
population.
It is unknown whether ablation of inducible VT in primary
prophylaxis patients can avoid ICD implantation. In a small
series23 of 38 primary prevention ICD patients with structural
heart disease, 18 of whom had undergone catheter ablation of
inducible VT, only 5% of these patients received appropriate
shock compared to 45% without catheter ablation (p ¼ 0.018)
after a mean follow-up of 50 months. These preliminary data
however do not allow us to conclude that VT ablation can be
used as first line therapy to avoid ICD implantation.
3.2. Patients with non-ischemic cardiomyopathy
Data supporting prophylactic ICD implantation in patients
with non-ischemic cardiomyopathy are less strong as
compared to ischemic heart disease. Three studies (CAT,24
AMIOVIRT25 and DEFINITE25) evaluated prophylactic ICD im-
plantation in a total of approximately 660 patients with LVEF
30e35% with or without documented non-sustained VT. All
showed a non-significant trend in reduced mortality in the
ICD arms. SCD-HeFT26 was a large trial that evaluated pro-
phylactic ICD implantation in patients with NYHA II-III heart
failure and LVEF 35% and that randomized 2521 patients to
conventional therapy vs. amiodarone vs. an ICD. The trial
showed a survival benefit with ICD therapy, and approxi-
mately half of these patients had non-ischemic cardiomyop-
athy without any significant difference in outcome compared
to those with ischemic heart disease. These two subgroups
analyzed separately only showed a trend in improved
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 2es 8 7 S85mortality, as was also the case in patients with an LVEF of
30e35%. Current guidelines state that:
Patients with non-ischemic dilated cardiomyopathy who have an
LVEF<35% and who are in NYHA functional Class II or III have a
class I (level of evidence B) indication for prophylactic ICD im-
plantation. Patients who are in NYHA functional class I have a
class IIb indication (level of evidence C).
The other question that arises in patientswith heart failure
is whether cardiac resynchronization therapy (CRT) is indi-
cated. The European guidelines have recently been updated,27
but are outside the scope of this review.
As can be appreciated from Figs. 1 and 2, that efficacy of
ICDs in primary prevention trials is comparable, if not higher,
than for that of secondary prevention.4. Other considerations
4.1. Individual patient decision-making
The guidelines discussed above should serve as an outline
to help in decision-making. Indications for an ICD should be
considered individually in each patient taking into account
factors such as patient age, comorbidities (which will mitigate
effectiveness of ICD therapy28), psychological profile, quality
of life, access to healthcare (mandatory for ICD follow-up) etc.4.2. Device follow-up
A crucial but sometimes neglected aspect of ICD therapy is
optimal programming and follow-up. Programming of
arrhythmia detection and therapy settings has been shown to
significantly affect mortality,29 as well as morbidity in terms
of inappropriate shocks.29e31 Troubleshooting of ICD follow-
up (e.g. interpretation of stored episodes) may be complex
and requires proper training of qualified personnel. National
societies should define standards to ensure that patients
receive optimal care. For example, the Working Group of
Pacing and Electrophysiology of the Swiss Society ofFig. 2 e Number of patients needed to treat (NNT) with an
ICD to save 1 life in the primary (left) and secondary
prevention trials (right).Cardiology stipulates that cardiologists who perform pace-
maker or ICD follow-up should have passed the EHRA
accreditation exam in cardiac pacing.32 Educational programs
are available to assist physicians in obtaining certification
(www.escardio.org/communities/EHRA/education/).4.3. Economic aspects
ICD therapy is expensive, although its cost-effectiveness is
acceptable according to Western standards.33 Nevertheless,
healthcare cost constraints are being faced worldwide, and
rational clinical decisions need to be made. Device manufac-
turers are facing increasing pressure on prices, although a
wider prescription of ICD therapy with greater volumes may
help in reducing unit cost. Simpler models (“shock boxes”)
may also be a cheaper solution than premium models, espe-
cially in patients with a primary prevention indication.
Adequate programming of these simpler devices needs
nevertheless to be performed to avoid inappropriate/unnec-
essary shocks. Re-use of explanted and resterilised ICDs with
at least 3 years projected battery longevity has been shown to
be safe,34 and may be an alternative if a new device is simply
not an option. Finally, political instances need to be made
aware of the importance of providing adequate funding for
this life-saving therapy.5. Conclusions
Randomized controlled trials have established ICD therapy
for secondary prevention of sudden death as well as for pri-
mary prevention in selected patients with structural heart
disease. Anti-arrhythmic therapy does not provide optimal
protection against ventricular arrhythmias in this setting,
even when arrhythmias are no longer inducible by EPS.
Catheter ablation of VT is a promising adjunct to ICD therapy
in order to reduce ICD shocks but does not replace device
therapy. Despite these facts, economic constraints in some
countries oblige physicians to prescribe anti-arrhythmic
therapy or catheter ablation if ICD therapy cannot be afforded.Conflicts of interest
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